The NMPA cleared testing of the HER3-targeting ADC with adebrelimab or a third-generation EGFR TKI, a move that could broaden Hengrui Medicine's lung cancer pipeline if later-stage data are positive.
verifying reliability
No specialized terms available for this topic.